Clinical Trials | January 12, 2026
Teva and Royalty Pharma partner in $500 million deal to fast-track vitiligo treatment
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
The integration unifies brand and field strategy, drives executional alignment, and delivers immediate impact measurement
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
Syrma Johari is a globally recognised medical device engineering and manufacturing organisation
Once finalized, cough syrups will no longer be available for over-the-counter sale
The decision secures legal protection in China for semaglutide, the blockbuster drug underpinning Novo Nordisk’s diabetes and obesity treatments
Subscribe To Our Newsletter & Stay Updated
